月度归档： 2026 年 6 月

IDMO Cellares and TScan Therapeutics will work together to evaluate automated clinical manufacturing of TSC-101, which is TScan’s lead TCR-T therapy candidate for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Traditionally, antibiotic discovery has involved the isolation of natural products from fungi and bacteria—largely actinomycetes. However, the perception that antibiotic-producing actinomycetes have yielded all they can, with little left to give, has motivated a recent shift toward novel antibiotic discovery processes.

In a new study published in  Nature Communications  titled, “ Native long-read RNA sequencing of human monocytes reveals activation-induced alternative splicing toward functional isoforms , ” researchers at University Medical Center (UMC) Utrecht have uncovered a previously underappreciated mechanism that helps immune cells respond rapidly to infections. The team showed that alternative RNA splicing plays a central role in shaping immune responses. The results provide new insights into immune-mediated diseases, such as infections, rheumatoid arthritis and lupus, and open the door to more targeted therapies.  

Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat inherited kidney diseases, through a collaboration that could generate more than $1.9 billion for the Boston biotech.

Targeting solid tumors remains one of oncology’s most persistent challenges. Even when a therapeutic antibody is well‑designed, and its molecular target is clear, the drug often struggles to reach its destination inside the dense, heterogeneous architecture of human tumors. Understanding why these agents fail in patients has been a longstanding blind spot in cancer pharmacology.